Form 4: RA Capital Reduces Stake in Werewolf Therapeutics

RA Capital Management has disclosed the sale of 564,449 shares of Werewolf Therapeutics (HOWL) across three trading days in May 2026.

Summary

• RA Capital Management, L.P. and associated entities sold a total of 564,449 shares of Werewolf Therapeutics common stock between May 8 and May 12, 2026.
• The sales were executed at weighted average prices ranging from $0.64 to $0.71 per share.
• Following these transactions, the reporting persons maintain a significant beneficial ownership position of over 6.1 million shares.
• The transactions were conducted by RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as bearish due to the significant volume of shares sold by a major institutional holder, which often precedes or reflects a lack of confidence in near-term upside.

Positives

• The reporting entities continue to hold a substantial remaining stake in the company, indicating ongoing, albeit reduced, investment interest.

Negatives

• Significant insider/major shareholder selling pressure, with over half a million shares offloaded in a three-day period.
• The sales were executed at price levels below $1.00, reflecting a low valuation environment for the issuer.

Risks

• Continued divestment by a major institutional shareholder may exert downward pressure on the stock price.
• The low trading price suggests potential challenges in maintaining market confidence or meeting exchange listing requirements.

Future Outlook

No specific forward-looking guidance regarding the company's operations was provided in this ownership disclosure.

Industry Context

StockSavvy.ai notes that institutional divestment in small-cap biotech firms often signals a rebalancing of portfolio risk or a lack of near-term catalysts, which can negatively impact retail investor sentiment.

Comparison to Industry Standards

• The selling activity is consistent with standard portfolio management practices for venture-backed biotech firms where institutional investors trim positions as they reach maturity or reallocate capital.
• The price point of under $1.00 is common for early-stage clinical biotech companies facing capital market headwinds.

Stakeholder Impact

• Shareholders may experience increased volatility due to the institutional selling pressure.
• The reduction in stake by a major investor may influence the perception of the company's long-term prospects.

Next Steps

• Monitor future Form 4 filings to determine if RA Capital continues to liquidate its position.

Key Dates

Recommendation

While the selling is significant, it is a standard portfolio adjustment. Investors should hold until further clarity on the company's clinical pipeline progress is provided, as the current price reflects high risk.

Keywords

Werewolf Therapeutics, HOWL, RA Capital Management, Insider Selling, Biotech, Form 4, Equity Transaction